

3-16-07

IFW

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Label No. EV 756034636 USus, on the date shown below in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: March 14, 2007

Signature:

(Peter C. Lauro)

Docket No.: 65350US(54086)
(PATENT)**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**In re Patent Application of:
Michael V. Agrez

Application No.: 10/575,736

Confirmation No.: 9415

Filed: April 13, 2006

Art Unit: N/A

For: *METHODS AND AGENTS FOR THE
TREATMENT OF CANCER*

Examiner: Not Yet Assigned

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§1.56, 1.97 and 1.98, Applicant invites the attention of the Patent and Trademark Office to the references listed on the attached PTO/SB/08. Applicant respectfully requests that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Supplemental Information Disclosure Statement is filed more than three months after the date of entry of the national stage of the corresponding PCT application, BUT before the mailing date of the first Office Action on the merits. (37 C.F.R. §1.97(c)).

In accordance with 37 C.F.R. §1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 C.F.R. §1.98(a)(2).

Applicant notes that references BD, CF and CE2 were cited in a Search Report issued during prosecution of GB patent No. 2409679, which issued from GB application

No. 422989.4, which corresponds to the instant application. A copy of the GB Search Report (ref. BI) is enclosed for the Examiner's convenience. The remaining references cited on the GB Search Report were made of record in the Information Disclosure Statement filed on April 13, 2006.

In accordance with 37 C.F.R. §1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(a) exists. In accordance with 37 C.F.R. §1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.


Applicant submits that the Supplemental Information Disclosure Statement is in compliance with 37 C.F.R. §1.98 and respectfully requests that the Examiner consider and make of record the listed references.

Applicant believes that no fees are required for consideration and entry of this Supplemental Information Disclosure Statement. Nevertheless, the Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 65350US(54086). A duplicate copy of this paper is enclosed.

Dated: March 14, 2007

Respectfully submitted,

By



Peter C. Lauro, Esq.

Registration No.: 32,360


EDWARDS ANGELL PALMER & DODGE LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Attorneys/Agents For Applicant



Application No. (if known): 10/575,736

Attorney Docket No.: 65350US(54086)

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV 756034636 USus in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on _____
Date

Signature

Peter C. Lauro, Esq.

Typed or printed name of person signing Certificate

32,360

Registration Number, if applicable

(617) 439-4444

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Supplemental Information Disclosure Statement (2 pages)
Citation (PTO/SB/08/A/B) by Applicant (115 References and GB Search Report) (6 pages)
Copies of 99 References and GB Search Report



PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/575,736	
			Filing Date	April 13, 2006	
			First Named Inventor	Michael V. Agrez	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	6	Attorney Docket Number	65350US(54086)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA*	US-5,593,884	01-14-1997	Karin et al.	
	AB*	US-2004/0147435		Hawiger et al.	
	AC*	US-5,807,746	09-15-1998	Lin et al.	
	AD*	US-5,962,643	10-05-1999	Sheppard et al.	
	AE*	US-6,007,991	12-28-1999	Sivaraman et al.	
	AF*	US-6,043,339	03-28-2000	Lin et al.	
	AG*	US-6,248,558	06-19-2001	Lin et al.	
	AH*	US-6,312,956	11-06-2001	Lane	
	AI*	US-6,339,148	01-15-2002	Sheppard et al.	
	AJ*	US-6,432,680	08-13-2002	Lin et al.	
	AK*	US-6,495,518	12-17-2002	Hawiger et al.	
	AL*	US-6,576,432	06-10-2003	Sheppard et al.	
	AM*	US-6,596,277	07-22-2003	Sheppard et al.	
	AN*	US-6,639,056-A1	10-28-2003	Sheppard et al.	
	AO*	US-6,780,843-A1	08-24-2004	Lin et al.	
	AP*	US-6,787,322-A1	09-07-2004	Sheppard et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO 91/19008		BOULTON		
	BB	WO 92/12236		SHEPPARD		
	BC	WO 95/34295		LIN		
	BD	WO 98/16241		VANDERBILT UNIVERSITY		
	BE	WO 99/09214		MCKAY		
	BF	WO 99/49879		LIN		
	BG	WO 00/59549		MCKAY		
	BH	WO 01/37821		HAWIGER		
	BI	GB Search Report				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city	T ²
Examiner Signature	Date Considered		

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/575,736	
			Filing Date	April 13, 2006	
			First Named Inventor	Michael V. Agrez	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	2	of	6	Attorney Docket Number	65350US(54086)

Initials		and/or country where published.	
	CA	Agrez, M., et al., "The $\alpha_v\beta_6$ integrin promotes proliferation of colon carcinoma cells through a unique region of the β_6 cytoplasmic domain". J. Cell. Biol. 127, No. 2, pp.547-556 (1994).	
	CB	Agrez, M.V., "Cell adhesion molecules and colon cancer", A.N.Z.J. Surgery 66, 789-796 (1996).	
	CC	Agrez, et al., "The $\alpha_v\beta_6$ integrin induces gelatinase B secretion in colon cancer cells", Int. J. Cancer 81 (1), 90-7 (1999).	
	CD	Agrez, M.V. et al., "Colorectal cancer and the integrin family of cell adhesion receptors: current status and future directions", European Journal of Cancer 30A, 2166-2170 (1994).	
	CE	Agrez, M.V. et al., "Multiplicity of fibronectin-binding α_v integrin receptors in colorectal cancer", Br. J. Cancer 73, 887-892 (1996).	
	CF	Ahmed, N. et al., "Direct integrin $\alpha_v\beta_6$ - ERK binding: implications for tumour growth". Oncogene 21, 1370-1380 (2002).	
	CG	Bookstein, R. et al, "p53 gene therapy <i>in vivo</i> for hepatocellular and liver metastatic colorectal cancer", Seminars Oncol. 23, 66-77 (1996).	
	CH	Boudreau, N.J and Jones, P.L., "Extracellular matrix and integrin signalling: the shape of things to come". Biochem. J. 339, 481-488 (1999).	
	CI	Boulton, T.G., et al., "ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF", Cell 65, 663-675 (1991).	
	CJ	Boulton, T.G., et al., "Mitogen-activated protein kinase 1," (EC 2.7.1) (1991) (Swiss Prot Acc No. P27703).	
	CK	Bruess, J.M., et al., "The integrin $\alpha_6\beta_1$, is necessary for the matrix-dependent activation of FAK and MAP Kinase and the migration of human hepatocarcinoma cells," Hepatology, Jul 34(1), 42-9 (2001).	
	CL	Carlone, V. et al., "The Integrin, $\alpha_6\beta_1$, is necessary for the matrix-dependent activation of FAK and MAP kinase and the migration of human hepatocarcinoma cells. Hepatology. Vol. 34, No. 1, 42-49 (2001).	
	CM	Chen et al., "Distinct structural requirements for interaction of the integrins $\alpha_5\beta_1$, $\alpha_v\beta_5$, and $\alpha_v\beta_6$ with central cell binding domain in fibronectin," Cell Adhesion and Communication, Vol. 4, Nos. 4-5, pp 237-250 (1996).	
	CN	Cone et al., "Effects of β subunit cytoplasmic domain deletions on the recruitment of the integrin $\alpha_v\beta_6$ to focal contact", Cell Adhesion and Communication, Vol. 2, pp. 101-113 (1994).	
	CO	Coppolino et al., "Bi-directional signal transduction by integrin receptors," The International Journal of Biochemistry & Cell Biology, Vol. 32, pp 171-188 (2000).	
	CP	Coppolino, M. et al., "Inducible interaction of integrin $\alpha_2\beta_1$ with calreticulin. Dependence of the activation state of the integrin", J. Biol. Chem. 270, 23132-23138 (1995).	
	CQ	Dedhar, S. and Hannigan, G.E., "Integrin cytoplasmic interactions and bidirectional transmembrane signalling". Curr. Op. Cell Biol. Vol. 8, No. 5, 657-669 (1996)	
	CR	Dixit et al., "Identification of a sequence within the integrin β_6 subunit cytoplasmic domain that is required to support the specific effect of $\alpha_v\beta_6$ on proliferation in three-dimensional culture", J Biol. Chem., Vol 271, No. 42, pp 25976-25980 (1996).	
	CS	Eliceiri, B.P., et al., "The role of α_v integrins during angiogenesis: insights into potential mechanisms of action and clinical development," J Clin Invest (1999), 103(9), 1227-30.	
	CT	Eliceiri, B.P., et al., "Integrin $\alpha_v\beta_3$ requirement for sustained mitogen activated protein kinase	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/575,736	
			Filing Date	April 13, 2006	
			First Named Inventor	Michael V. Agrez	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	3	of	6	Attorney Docket Number	65350US(54086)

		activity during angiogenesis," J Cell Biol (1998), 140(5): 1255-63.	
	CU	Erker, J.C. et al., Database GenBank 'Online', "Polyprotein GB virus c/Hepatitis C virus", Database Accession No. AAC55951 (13 November 1996) (Abstract)	
	CV	Fodstad, O. et al., Database Geneseq 'Online', "CAPL gene 5' splice site antisense oligonucleotide", Database Accession No. AAT33333 (12 November 1996)	
	CW	Friedlander, M., et al., "Definition of two angiogenic pathways by distinct a v integrins," Science (1995), 270(5241): 1500-2.	
	CX	Gamble, J. R. et al., "Regulation of <i>in vitro</i> capillary tube formation by anti-integrin antibodies", J. Cell Biol. 121, 931-943 (1993).	
	CY	Garrington, T.P. et al., "Organization and regulation of mitogen-activated protein kinase signaling pathways", Curr. Opin. Biol. 11, 211-218 (1999).	
	CZ	Giancotti, F.G. et al., "Integrin signaling", Science 285, 1028-1032 (1999). Gorgziglia and Kapikian, J., Virol. 66, 4407-4412 (1992).	
	CA1	Gonzalez, F.A., "H Sapiens 40kDa protein kinase related to rat ERK2," (1992) (GenPept Acc No. CAA77753).	
	CB1	Gorgziglia, M. and Kapikian, A.Z., "Expression of the OSU rotavirus outer capsid protein VP4 by an adenovirus recombinant". J. Virol., pp 4407-4412, July (1992)	
	CC1	Gotoh et al., "Cross-Linking of Integrins Induces Tyrosine Phosphorylation of the Proto-Oncogene Product Vav and the Protein Tyrosine Kinase Syk in Human Factor-dependent Myeloid Cells", Cell Growth and Differentiation, Vol. 8, pp. 721-729 (1997).	
	CD1	Grammer, T.C. et al., "Evidence for MEK-independent pathways regulating the prolonged activation of the ERK-MAP kinases", Oncogene 14, 1635-1642 (1997).	
	CE1	Gu, J. et al., "Tumor suppressor PTEN inhibits integrin - and growth factor - mediated nitrogen activated protein (MAP) kinase signalling pathways". J. Cell Biol. Vol. 143, No. 5, 1375-1383 (1998)	
	CF1	Guan, J.L. et al., "Regulation of focal adhesions-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation", Nature 358, 690-692 (1992).	
	CG1	Gupta, K., et al., "VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling," Exp Cell Res (1999), 247(2): 495-504.	
	CH1	Hannigan, G.E. et al., "Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase", Nature 379, 91-96 (1996).	
	CI1	von Heijne, G., "The Signal Peptide". Topical Review. J. Membrane Biol. 115, 195-201 (1990)	
	CJ1	Hemler, M.E., "Integrin associated proteins", Curr. Opin. Biol. 10, 578-585 (1998).	
	CK1	Hergott, G.J. et al., "Inhibition of retinal pigment epithelial cell migration and proliferation with monoclonal antibodies against the beta 1 integrin subunit during wound healing in organ culture", Invest. Ophthalmol. Vis. Sci. 34, 2761-2768 (1993).	
	CL1	Horwitz, A. et al., "Interaction of plasma membrane fibronectin receptor with a talin-a transmembrane linkage", Nature 320, 531-533 (1986).	
	CM1	Howe, A. et al., "Integrin signaling and cell growth control", Curr. Opin. Biol. 10, 220-231 (1998).	
	CN1	Hughes, P.E. and Pfaff, M., "Integrin affinity modulation". Trends. Cell Biol. Vol. 8, No. 9, 359-364 (1998)	
	CO1	Ishii, T.. et al.. "Integrin-linked kinase controls neurite outgrowth in N1E-115 neuroblastoma	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/575,736	
			Filing Date	April 13, 2006	
			First Named Inventor	Michael V. Agrez	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	4	of	6	Attorney Docket Number	65350US(54086)

		cells," J. Biol. Chem. 276(46): 42994-43003 (2001).	
	CP1	Johnson O.L. and Tracey, M.A., Encyclopaedia of Controlled Drug Delivery. Vol. 2, pp. 816-833. Edith Mathiowitz, John Wiley & Sons, Inc. New York (1999)	
	CQ1	Kerr, et al., "Novel small a v integrin antagonists: Comparative anti-cancer efficacy with known angiogenesis inhibitors", Anticancer Res 19 (2A), 959-68, (1999).	
	CR1	Knezevic, I. et al., "Direct binding of the platelet integrin alpha lib beta 3 (Pella) to talin. Evidence that interaction is mediated through the cytoplasmic domains of both alpha lib and beta 3", J. Biol. Chem. 271, 16416-16421 (1996).	
	CS1	Kornberg, L. et al., "Cell adhesion or integrin clustering increases phosphorylation of a focal adhesion-associated tyrosine kinase", J. Biol. Chem. 267, 23439-23442 (1992).	
	CT1	Lin et al., "Integrin-mediated Activation of MAP Kinase Is Independent of FAK: Evidence for Dual Integrin Signaling Pathways in Fibroblasts", J. Cell. Biol., Vol. 136, No. 6, (1997)	
	CU1	Lin, Y-Z et al., "Inhibition of nuclear translocation of transcription factors NF- κ B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence". J. Biol. Chem. Vol. 230, No. 24, 14255-14258 (1995)	
	CV1	Liu, S., et al., "Binding of paxillin to α_4 integrins modifies integrin-dependent biological responses". Nature. Vol. 402, 666-681 (1999).	
	CW1	Liu, X-Y, et al., "Identification of a functionally important sequence in the cytoplasmic tail of integrin β_3 by using cell-permeable peptide analogs". Proc. Natl. Acad. Sci. USA. Vol. 93, 11819-11824 (1996)	
	CX1	Loftus, J.C et al., "Integrin-mediated cell adhesion: the extracellular face", J. Biol. Chem. 269, 25235-25238 (1994).	
	CY1	Lub, M., et al; "Cytoplasmic tails of β_1 , β_2 , and β_7 integrins differentially regulate LFA-1 function in K562 cells". Mol. Biol. Cell, Vol. 8, 719-728 (1997)	
	CZ1	Maniero, F., et al., "The coupling of $\alpha_6\beta_4$ integrin to Ras-MAP kinase pathways mediated by Shc controls keratinocyte proliferation". EMBO J. Vol. 16, No. 9, 2365-2375 (1997)	
	CA2	Marcantonio, E.E., et al., "Mapping of the functional determinants of the integrin β_1 cytoplasmic domain by site-directed mutagenesis". Cell Reg. Vol. 1, 591-604 (1990)	
	CB2	Mastrenghelo, A.M., et al., "Amino acid motifs required for isolated β cytoplasmic domains to regulate 'in trans' β_1 integrin conformation and function in cell attachment". J. Cell. Science, 112, 217-229 (1999)	
	CC2	Meurers, B.H. et al., Database GenBank 'Online'. "Myosin heavy chain 12 'Homo Sapiens'", Database Accession No. CAA69036 (8 January 1997) (Abstract)	
	CD2	Miranti, C.K. et al., "Protein Kinase C regulates integrin-induced activation of the extracellular regulated kinase pathway upstream of Shc", J. Biol. Chem. 274, 10571-10581 (1999).	
	CE2	Niu, J., et al., "Integrin expression in colon cancer cells is regulated by the cytoplasmic domain of the β_6 integrin submit". Int. J. Cancer. 99, 529-537 (2002)	
	CF2	Oda, K. et al., Database GenBank 'Online', "CoxII intron2 ORF 'Marchantia polymorpha!", Database Accession No. AAC09431 (2 April 1998) (Abstract)	
	CG2	Otey, C.A. et al., "An interaction between alpha-actinin and beta 1 integrin subunit in vitro", J. Cell Biol. 111, 721-729 (1990).	
	CH2	O'Toole, T.E., et al., "Regulation of integrin affinity states through an NPXY motif in the β subunit cytoplasmic domain". J. Biol. Chem. Vol. 270, No. 15, 8553-8558 (1995)	
	CI2	Pagès, G., et al., "Signaling angiogenesis via p42/p44 MAP kinase cascade." Ann NY Acad	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/575,736	
			Filing Date	April 13, 2006	
			First Named Inventor	Michael V. Agrez	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	5	of	6	Attorney Docket Number	65350US(54086)

		Sci, 902: 187-200, (2000).	
	CJ2	Pardi, R., et al., "Conserved regions in the cytoplasmic domains of the leukocyte integrin $\alpha_L\beta_2$ are involved in endoplasmic reticulum retention, dimerization, and cytoskeletal association". J. Immunol. Vol. 155, No. 3, 1252-1263 (1995)	
	CK2	Patil, S., et al., "A double mutation of the NPLY motif in the integrin β_3 cytoplasmic tail abolishes post-ligand binding events of β_3 integrins". Vol. 7, No. Suppl. p.248A (1996) (Abstract)	
	CL2	Payne, D.M. et al., "Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase)", EMBOJ 10, 885-892 (1991).	
	CM2	Pfaff, M. et al., "Integrin beta cytoplasmic domains differentially bind to cytoskeletal proteins", J. Biol. Chem. 273, 6104-6109 (1998).	
	CN2	Pillinger, M., et al., "Modes of action of aspirin-like drugs: Salicylates inhibit Erk activation and integrin-dependent neutrophil adhesion". Proc. Natl. Acad. Sci. USA. Vol. 95, 14540-14545 (1998)	
	CO2	Redlitz, A., et al., "Angiostatin diminishes activation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular endothelial cells." J Vasc Res, 36(1): 28-34, (1999).	
	CP2	Reszka, A.A. et al., "Identification of amino acid sequences in the integrin beta 1 cytoplasmic domain implicated in cytoskeletal association", J. Cell Biol. 117, 1321-1330 (1992).	
	CQ2	Roberts, M.S., et al., "ERK1 associates with $\alpha_v\beta_3$ integrin and regulates cell spreading on vitronectin". J. Biol. Chem. Vol. 278, No. 3, 1975-1985 (2003)	
	CR2	Rojiani, M.V. et al., "In vitro interaction of a polypeptide homologous to human Ro/SS-A antigen (calreticulin) with a highly conserved amino acid sequence in the cytoplasmic domain of integrin alpha subunits", Biochemistry 30, 9859-9866 (1991).	
	CS2	Schaller, M.D. et al., "Focal adhesion kinase and paxillin bind to peptides mimicking beta integrin cytoplasmic domains", J. Cell Biol. 130, 1181-1187 (1995).	
	CT2	Sebolt-Leopold, J.S., et al., "Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo". Nature Medicine. Vol. 5, No. 7, 810-816 (1999)	
	CU2	Sheppard, D. et al., "Complete amino acid sequence of a novel integrin β subunit (β_6) identified in epithelial cells using the polymerase chain reaction", J. Biol. Chem. 265, 11502-11507 (1990).	
	CV2	Sugiura, N., et al., "Mus musculus DNA for ERK2," exon 7. (GenPept Acc No. BAA22620) (1997) (Abstract).	
	CW2	Swanson, R. et al., Database GenBank 'Online', "UL97 homolog 'Rhesus cytomegalovirus!", Database Accession No. AAC05259 (7 March 1998) (Abstract)	
	CX2	Tada, M. et al., Database GenBank 'Online', "Homeobox protein B1X3 'Xenopus laevis'", Database Accession No. AAC61703 (29 September 1998) (Abstract)	
	CY2	Tahiliani, P.D., et al., "The role of conserved amino acid motifs within the integrin β_3 cytoplasmic domain in triggering focal adhesion kinase phosphorylation". J. Biol. Chem. Vol. 272, No. 12, 7892-7898 (1997)	
	CZ2	Tanaka, K., et al., "Roles of extracellular signal-regulated kinase 1/2 and p38 nitrogen-activated protein kinase in the signal transduction of basic fibroblast growth factor in endothelial cells during angiogenesis". Jpn. J. Cancer Res. 90, 647-654 (1999)	
	CA3	Trikha. et al.. "Role of $\alpha_{IIb}\beta_3$ integrin in prostate cancer metastasis". Prostate 35 (3). 185-92.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/575,736	
			Filing Date	April 13, 2006	
			First Named Inventor	Michael V. Agrez	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	6	of	6	Attorney Docket Number	65350US(54086)

		(1998).	
	CB3	Townsend, P.A., et al; " β 1 integrin antisense oligodeoxynucleotides: utility in controlling osteoclast function". Eur. J. Cell. Biol. Vol.78, 485-496 (1999)	
	CC3	Vamer, J.A. et al., "Integrin alpha 5 beta 3 expression negatively regulates cell growth: reversal by attachment to fibronectin", Mol. Biol. Cell 6, 725-740 (1995).	
	CD3	Vignoud, L., et al., "NPXY motifs control the recruitment of the $\alpha_5\beta_1$ integrin in focal adhesions independently of the association of talin with the β_1 chain". J. Cell. Sci. 110, 1421-1430 (1997)	
	CE3	Wang, A. et al., "Differential regulation of airway epithelial integrins by growth factors", Am. J. Respir. Cell & Mol. Biol. 15, 664-672 (1996).	
	CF3	Wary, K.K. et al., "The adaptor protein Shc couples a class of integrins to the control of cell cycle progression", Cell 87, 733-743 (1996).	
	CG3	Weinacker et al. Role of the integrin alpha v beta 6 in cell attachment to fibronectin. J. Biol. Chem. 269:6940-6948, (1994).	
	CH3	Yokosaki et al., "Differential Effects of the Integrins $\alpha\beta$, $\alpha v\beta$, $\alpha v\beta 6$ on Cell Proliferative Responses to Tenascin: Roles of the β Subunit Extracellular and Cytoplasmic Domains," J. Biol. Chem., vol 271, no. 39, pp. 24144-24150, (1996).	
	CI3	Yu, Y., et al., "Map Kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor," J Cell Physiol, 178(2): 235-46, (1999).	
	CJ3	Zage, P.E. and Marcantonio, E. E., "The membrane proximal region of the integrin β cytoplasmic domain can mediate oligomerization". Cell. Adh. And Comm. Vol. 5, 335-347 (1998)	
	CK3	Zhang, et al., "Retroviral transfer of antisense integrin $\alpha 6$ or $\alpha 8$ sequences results in laminar redistribution or clonal cell death in developing brain", J. Neurosci. 18(17), 6928-38, (1998).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--